CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy. Willier S, Rothamel P, Hastreiter M, Wilhelm J, et al. Blood 2021;137:1037-1049.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Willier S, Rothamel P, Hastreiter M, Wilhelm J, et al. CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy. Blood 2021;137:1037-1049.
PMID: 33094319